AUS
NZ
UK
CA
USA
IND
Racura Oncology Limited (ASX:RAC), a biopharmaceutical company in Phase 3 clinical development focused on cancer silencing therapies, has scheduled two key investor events in New Zealand for August 2026. Executive Chair Dr Peter Smith will lead a morning tea briefing for current and prospective shareholders in Auckland on 5 August 2026, followed by a presentation at the 20th Bioshares Biotech Summit in Queenstown on 7 August 2026. These occasions will provide important updates on Racura's lead compound RC220 and its clinical programs targeting three oncology indications. Investors are encouraged to register early due to limited availability.<\/p> <\/div>
Key Points<\/h3>
- Company: Racura Oncology Limited (ASX:RAC)<\/li>
- Dr Peter Smith to host Auckland investor briefing on Wednesday, 5 August 2026 at 10:30AM; RSVPs due by Friday, 10 July 2026<\/li>
- Dr Smith to present at the 20th Bioshares Biotech Summit in Queenstown on Friday, 7 August 2026 at 12:15PM<\/li>
- Briefings to cover RC220's Phase 3 AML program, HARNESS-1 Phase 1 trial in EGFR-mutant NSCLC, and CPACS cardioprotective trial<\/li>
- Dr Smith will chair Session 4: Improving Lifespan at the Bioshares Summit on Thursday, 6 August 2026 from 4:30PM to 5:45PM<\/li>
- Investors should anticipate details on near-term catalysts to be revealed at the Auckland briefing<\/li>
<\/ul>
<\/div>
Racura Oncology to Host Auckland Morning Tea Investor Briefing on 5 August 2026<\/h2>
Racura Oncology has announced an investor briefing in Auckland, New Zealand, scheduled for Wednesday, 5 August 2026. The event will be conducted in a morning tea format, starting at 10:30AM with registration from 10:15AM. The exact venue in central Auckland will be confirmed closer to the date, as per the company update released on 6 July 2026.<\/p>
The briefing is open to all existing shareholders and potential investors, but attendance is limited. Interested parties are requested to RSVP by Friday, 10 July 2026, via email to [email protected]. Investors located in New Zealand or planning to be in Auckland in early August are advised to register promptly due to capacity limits.<\/p>
Dr Peter Smith to Present RC220 Strategy and Upcoming Clinical Catalysts<\/h2>
Executive Chair Dr Peter Smith will lead the Auckland briefing, outlining Racura's corporate strategy and providing updates on the rapid clinical development of RC220, the company’s proprietary (E,E)-bisantrene formulation. RC220 is a small molecule anticancer agent that functions primarily through G4-DNA and RNA binding to effectively silence the cancer growth regulator MYC.<\/p>
Importantly, Dr Smith is expected to disclose the company’s near-term catalyst schedule at the Auckland briefing. This information will be closely watched by shareholders monitoring the progress of Racura’s three active clinical programs. While specific catalysts and timelines were not detailed in the recent update, these will be shared during the event.<\/p>
Phase 3 AML Program for RC220 Targeting c-MYC Silencing Highlighted<\/h2>
A key focus at the Auckland briefing will be Racura's Phase 3 clinical program for acute myeloid leukaemia (AML). RC220 targets c-MYC silencing and represents a central component of the company’s oncology pipeline. AML remains a significant unmet medical need, and Racura positions RC220 as a promising treatment option for this indication.<\/p>
Previous data indicate that (E,E)-bisantrene has shown therapeutic activity in cancer patients with a well-characterized safety profile. The Phase 3 AML program is the most advanced clinical effort by Racura, and updates from Dr Smith are expected to be of high interest to investors tracking regulatory progress.<\/p>
HARNESS-1 Phase 1 Trial Combining RC220 with Tagrisso in EGFR-Mutant NSCLC<\/h2>
Dr Smith will also provide an update on the HARNESS-1 Phase 1a\/b trial evaluating RC220 combined with Tagrisso® (osimertinib) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). EGFR-mutant NSCLC is a common lung cancer subtype, and combining RC220 with established agents like Tagrisso is a strategic expansion beyond AML.<\/p>
The HARNESS-1 study focuses on safety, tolerability, and early activity signals. No specific enrollment numbers, dosing cohort progress, or interim results were disclosed in the recent update, but attendees at the Auckland briefing and Bioshares Summit will receive the latest information directly from Dr Smith.<\/p>
CPACS Trial Evaluating RC220 with Doxorubicin for Cardioprotection in Solid Tumours<\/h2>
The CPACS trial, also to be discussed, assesses RC220 in combination with doxorubicin. This program aims to demonstrate enhanced anticancer effects alongside cardioprotective benefits for solid tumour patients. Doxorubicin is a widely used chemotherapy agent known for cardiotoxicity risks, making cardioprotection a significant clinical advantage if proven.<\/p>
CPACS is a Phase 1a\/b trial targeting solid tumours, broadening Racura’s potential patient base beyond AML and lung cancer. Investors will be attentive to updates on trial progress, enrollment, and early safety data during Dr Smith’s presentations. Further details were not provided in the company update.<\/p>
Dr Peter Smith to Present at 20th Bioshares Biotech Summit in Queenstown<\/h2>
The day after the Auckland briefing, Dr Peter Smith will present on Racura Oncology at the 20th Bioshares Biotech Summit in Queenstown, New Zealand, on Friday, 7 August 2026 at 12:15PM. This event offers increased exposure to biotechnology investors and industry professionals.<\/p>
The Bioshares Biotech Summit is a prominent event in the Australian and New Zealand biotech investment calendar, offering a platform for listed biotech firms to engage with institutional and sophisticated investors. Racura’s participation highlights its active investor relations efforts as it advances its clinical pipeline. Investors interested in one-on-one meetings during the summit should contact Jane Lowe at [email protected].<\/p>
Dr Smith to Chair Session 4: Improving Lifespan on 6 August at Bioshares Summit<\/h2>
In addition to his presentation, Dr Smith will chair Session 4: Improving Lifespan on Thursday, 6 August 2026, from 4:30PM to 5:45PM at the Bioshares Summit. This role places Racura at the forefront of discussions on longevity and lifespan extension within the biotech sector.<\/p>
Dr Smith’s dual role as presenter and session chair positions Racura Oncology prominently within the New Zealand and Australian biotech investment community. This engagement may enhance the company’s profile among institutional investors and potential strategic partners, as Racura explores partnerships, licensing, or commercial mergers to accelerate global access to RC220.<\/p>
RC220 Supported by Strong IP and Global Research Collaborations<\/h2>
Racura’s clinical programs are underpinned by composition of matter intellectual property providing approximately 20 years of patent protection for (E,E)-bisantrene. This IP is critical for the long-term commercial viability of RC220.<\/p>
The company has established a network of academic and research collaborators including Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. This extensive collaboration underscores scientific interest in RC220’s mechanism and supports its development credibility ahead of the investor events.<\/p>
Key Takeaways for Investors Post-August 2026 New Zealand Events<\/h2>
The Auckland briefing and Bioshares Summit presentations mark important near-term milestones in Racura’s investor engagement. Investors should closely watch for disclosure of the near-term catalyst schedule, clinical updates on the Phase 3 AML program, HARNESS-1, and CPACS trial.<\/p>
Those unable to attend can monitor Racura’s ASX announcements and Interactive Announcements pages for any post-event releases. The company has not confirmed if presentation materials or recordings will be publicly available. Market reaction will depend on the content of disclosures made during the events.<\/p>
Racura Oncology to Host Auckland Morning Tea Investor Briefing on 5 August 2026<\/h2>
Racura Oncology has announced an investor briefing in Auckland, New Zealand, scheduled for Wednesday, 5 August 2026. The event will be conducted in a morning tea format, starting at 10:30AM with registration from 10:15AM. The exact venue in central Auckland will be confirmed closer to the date, as per the company update released on 6 July 2026.<\/p>
The briefing is open to all existing shareholders and potential investors, but attendance is limited. Interested parties are requested to RSVP by Friday, 10 July 2026, via email to [email protected]. Investors located in New Zealand or planning to be in Auckland in early August are advised to register promptly due to capacity limits.<\/p>
Dr Peter Smith to Present RC220 Strategy and Upcoming Clinical Catalysts<\/h2>
Executive Chair Dr Peter Smith will lead the Auckland briefing, outlining Racura's corporate strategy and providing updates on the rapid clinical development of RC220, the company’s proprietary (E,E)-bisantrene formulation. RC220 is a small molecule anticancer agent that functions primarily through G4-DNA and RNA binding to effectively silence the cancer growth regulator MYC.<\/p>
Importantly, Dr Smith is expected to disclose the company’s near-term catalyst schedule at the Auckland briefing. This information will be closely watched by shareholders monitoring the progress of Racura’s three active clinical programs. While specific catalysts and timelines were not detailed in the recent update, these will be shared during the event.<\/p>
Phase 3 AML Program for RC220 Targeting c-MYC Silencing Highlighted<\/h2>
A key focus at the Auckland briefing will be Racura's Phase 3 clinical program for acute myeloid leukaemia (AML). RC220 targets c-MYC silencing and represents a central component of the company’s oncology pipeline. AML remains a significant unmet medical need, and Racura positions RC220 as a promising treatment option for this indication.<\/p>
Previous data indicate that (E,E)-bisantrene has shown therapeutic activity in cancer patients with a well-characterized safety profile. The Phase 3 AML program is the most advanced clinical effort by Racura, and updates from Dr Smith are expected to be of high interest to investors tracking regulatory progress.<\/p>
HARNESS-1 Phase 1 Trial Combining RC220 with Tagrisso in EGFR-Mutant NSCLC<\/h2>
Dr Smith will also provide an update on the HARNESS-1 Phase 1a\/b trial evaluating RC220 combined with Tagrisso® (osimertinib) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). EGFR-mutant NSCLC is a common lung cancer subtype, and combining RC220 with established agents like Tagrisso is a strategic expansion beyond AML.<\/p>
The HARNESS-1 study focuses on safety, tolerability, and early activity signals. No specific enrollment numbers, dosing cohort progress, or interim results were disclosed in the recent update, but attendees at the Auckland briefing and Bioshares Summit will receive the latest information directly from Dr Smith.<\/p>
CPACS Trial Evaluating RC220 with Doxorubicin for Cardioprotection in Solid Tumours<\/h2>
The CPACS trial, also to be discussed, assesses RC220 in combination with doxorubicin. This program aims to demonstrate enhanced anticancer effects alongside cardioprotective benefits for solid tumour patients. Doxorubicin is a widely used chemotherapy agent known for cardiotoxicity risks, making cardioprotection a significant clinical advantage if proven.<\/p>
CPACS is a Phase 1a\/b trial targeting solid tumours, broadening Racura’s potential patient base beyond AML and lung cancer. Investors will be attentive to updates on trial progress, enrollment, and early safety data during Dr Smith’s presentations. Further details were not provided in the company update.<\/p>
Dr Peter Smith to Present at 20th Bioshares Biotech Summit in Queenstown<\/h2>
The day after the Auckland briefing, Dr Peter Smith will present on Racura Oncology at the 20th Bioshares Biotech Summit in Queenstown, New Zealand, on Friday, 7 August 2026 at 12:15PM. This event offers increased exposure to biotechnology investors and industry professionals.<\/p>
The Bioshares Biotech Summit is a prominent event in the Australian and New Zealand biotech investment calendar, offering a platform for listed biotech firms to engage with institutional and sophisticated investors. Racura’s participation highlights its active investor relations efforts as it advances its clinical pipeline. Investors interested in one-on-one meetings during the summit should contact Jane Lowe at [email protected].<\/p>
Dr Smith to Chair Session 4: Improving Lifespan on 6 August at Bioshares Summit<\/h2>
In addition to his presentation, Dr Smith will chair Session 4: Improving Lifespan on Thursday, 6 August 2026, from 4:30PM to 5:45PM at the Bioshares Summit. This role places Racura at the forefront of discussions on longevity and lifespan extension within the biotech sector.<\/p>
Dr Smith’s dual role as presenter and session chair positions Racura Oncology prominently within the New Zealand and Australian biotech investment community. This engagement may enhance the company’s profile among institutional investors and potential strategic partners, as Racura explores partnerships, licensing, or commercial mergers to accelerate global access to RC220.<\/p>
RC220 Supported by Strong IP and Global Research Collaborations<\/h2>
Racura’s clinical programs are underpinned by composition of matter intellectual property providing approximately 20 years of patent protection for (E,E)-bisantrene. This IP is critical for the long-term commercial viability of RC220.<\/p>
The company has established a network of academic and research collaborators including Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. This extensive collaboration underscores scientific interest in RC220’s mechanism and supports its development credibility ahead of the investor events.<\/p>
Key Takeaways for Investors Post-August 2026 New Zealand Events<\/h2>
The Auckland briefing and Bioshares Summit presentations mark important near-term milestones in Racura’s investor engagement. Investors should closely watch for disclosure of the near-term catalyst schedule, clinical updates on the Phase 3 AML program, HARNESS-1, and CPACS trial.<\/p>
Those unable to attend can monitor Racura’s ASX announcements and Interactive Announcements pages for any post-event releases. The company has not confirmed if presentation materials or recordings will be publicly available. Market reaction will depend on the content of disclosures made during the events.<\/p>
